Revenue surges 61%, but consolidated PAT loss widened QoQ—breakeven 2-3 quarters away
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Reaffirmed 3x Tritium growth + Q4 EBITDA breakeven from prior call (not raised). Delivered YoY loss improvement (₹83.1 Cr → ₹73.6 Cr) but QoQ deterioration. Hyderabad capex is planned/disclosed; Tritium turnaround narrative is 2+ years old.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Exicom delivered record 61% consolidated revenue growth and ₹1,400 Cr order book, supporting the 2–3 year structural narrative in energy transition (5G, EV, BESS). However, Q1 reported a -₹73.6 Cr consolidated loss, with PAT deteriorating QoQ by 35.5% despite revenue growth—driven by Hyderabad capex (₹10.3 Cr depreciation, ₹8.7 Cr parallel run costs) and Tritium inventory margin normalization. The core risk: management targets EBITDA/PAT breakeven in next 2 quarters (Q2–Q3 FY27), but this is unproven and timing is vague; if costs extend or Tritium trials stall, the loss could persist into H2.
₹331.1 Cr
Revenue · +61.2% YoY₹-73.6 Cr
Reported PAT · +11.5% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Revenue grew 61% YoY to ₹331 Cr (consolidated)
METDelivered ₹331.1 Cr, 61% growth confirmed. Strong order execution.
Consolidated EBITDA loss narrowed to ₹22.5 Cr (Q1 FY27)
METActual ₹21.9 Cr loss. Improvement from ₹38.6 Cr loss YoY, but QoQ margin deteriorated despite 61% growth.
Stand-alone PAT ₹4.9 Cr at 2.1% margin (turnaround)
MISSDelivered ₹4.9 Cr, 2.1% margin. But consolidated PAT is -₹73.6 Cr loss—Tritium dragging.
Tritium bookings doubled to USD 20M; revenue USD 10M
METBookings USD 20.8M (verified), revenue USD 10.5M. On track but trials still mid-stage; conversion risk unresolved.
EBITDA breakeven next 2 quarters (Q2 or Q3 FY27)
UnverifiedGuidance stated but not quantified. Hyderabad parallel costs (₹8.7 Cr) expected to phase out, but timing uncertain.
Critical Power order book ₹1,000+ Cr supports execution; exports to scale 8%→15%
OVERSTATEDOrder book ₹1,000 Cr cited; Q1 exports only ₹15 Cr (8% of Critical Power). Target is aspirational.
Earnings quality
What changed since the last call
Hyderabad plant capex drag intensifies in Q1
DowngradeParallel run cost (₹8.7 Cr) + depreciation jump (₹10 Cr) masks underlying business improvement. Prior call did not quantify these headwinds in full.
Tritium bookings momentum accelerates
UpgradeBookings nearly doubled USD 10M → USD 20.8M Q1. New product trials with Fortune 100 entering mid-stage. Prior call noted trials were early; now advanced.
Critical Power order book hits ₹1,400 Cr (consolidated)
UpgradePrior call alluded to large order wins; now quantified as ₹1,400 Cr for both stand-alone and Tritium. Provides 60+ months visibility.
EBITDA breakeven timeline narrowed: 'next 2 quarters' specified
NeutralPrior call: 'Tritium Q4, consolidated over next 2 quarters.' Current: 'Q2 or Q3 breakeven on consolidated.' Slightly more specific but range still 6+ months.
The Q&A
Analysts pressed hard on EBITDA deterioration (Taksh Gaur: broke even Q4, -₹22.5 Cr in Q1 despite 61% growth). Management blamed Q4 seasonality + Tritium inventory normalization but timeline vague. Suraj C questioned capacity numbers and depreciation levels; management partly deferred ('I'll come back to you'). Shashi Kant probed EV charger underutilization industry issue; management pivoted to product quality narrative, avoiding direct answer on macro headwinds. Overall: held up but cautious tone among analysts.
EBITDA breakeven timeline — Taksh Gaur, Brighter Mind Asset Management
PartialQ4 was seasonally strong. Tritium's low-cost inventory from acquisition has eroded. Consolidated breakeven expected next 2 quarters (Q2 or Q3). Tritium EBITDA breakeven Q4 FY27 based on order backlog.
Tritium order conversion — Taksh Gaur, Brighter Mind Asset Management
PartialCurrent backlog USD 20M + ongoing bookings + large strategic opportunities (Fortune 100 trials). Confident of 3x revenue and Q4 EBITDA breakeven. Trials expected to close CY27 Q1, revenue execution CY27.
Capacity utilization & expansion — Suraj C, Vijit Global Securities
Dodged222,000 is correct. 48,000 was single-shift; doubling is based on double-shift operation. Will follow up with exact answer.
Depreciation level justification — Suraj C, Vijit Global Securities
AnsweredStand-alone depreciation increase is normal (Hyderabad commissioning, only +₹10 Cr YoY). Tritium high depreciation due to R&D capitalization over 2-year product journey; expected to generate revenue CY27 Q1 onwards, amortizing depreciation.
EV business growth disconnect — Hemansh Jain, Indira Securities
AnsweredVehicle registration momentum just picked up Q1 (31,000 cars, highest ever). AC charger supply shorter value than DC. Q4 customers upfront ordered DC chargers due to forex/commodity risk → pulled Q1 demand forward. AC likely grew 30%; DC ~10%. Blended 15% is timing issue; growth continuing.
Charger industry underutilization — Shashi Kant, Brighter Mind Asset Management
PartialNetwork quality varies. Good networks (South, pan-India, conglomerate-owned) have 20%+ utilization (excellent). Older 2020–22 chargers are obsolete; 30–35% of deployed DC chargers non-functional per independent study. Exicom focuses on high-quality, reliable chargers. It's survival of fittest.
Guidance
Tritium 3x revenue growth by Q4 FY27 + CY27 start
MediumBased on USD 20M backlog + strategic trials pipeline. Conversion risk: trials mid-stage. No consolidated FY27 revenue target provided.
Critical Power exports 8% → 15% FY27
MediumQ1 export sales ₹15 Cr (8% of CP). Target is aspirational; depends on Africa, Middle East, Southeast Asia market acceleration.
Consolidated order book ₹1,400 Cr (as of June 30)
HighCritical Power ₹1,000+ Cr + Tritium backlog USD 20M (~₹166 Cr). Provides long-term revenue visibility.
Consolidated EBITDA breakeven next 2 quarters (Q2 or Q3 FY27)
LowDepends on Hyderabad parallel run costs phasing out. No quantification of margin bridge provided. If capex drag extends, target at risk.
Tritium EBITDA breakeven Q4 FY27
MediumCurrently USD 10M quarterly revenue with negative EBITDA. 3x growth would put revenue at USD 30M+. Margin profile not quantified.
Hyderabad parallel run costs (₹8.7 Cr Q1) to phase out over coming quarters
MediumTimeline for Gurgaum transition completion not specified. Costs could persist into Q2–Q3 if ramp slower than expected.
Risks the call surfaced
Execution risk: Tritium turnaround
HighTritium trials with Fortune 100 companies are mid-stage to advanced. Conversion to USD 20–30M contracts by CY27 is aspirational. Delays would push profitability inflection to H2+ FY27.
Cost structure: Hyderabad transition drag
HighHyderabad plant operational since Q4 FY26; parallel run with Gurgaum cost ₹8.7 Cr Q1, depreciation up 67% YoY. If transition takes 3+ quarters vs 2, breakeven delayed.
Supply chain & forex headwinds
MediumInput cost pressure (semiconductors, plastics, copper) cited as ongoing constraint. Forex headwinds offset by volume leverage but margins compressed YoY. Further rupee weakness could re-accelerate costs.
Working capital intensity
Medium57% revenue growth has lifted receivables; inventory built for Q3–Q4 order execution in parallel plants. If growth slows or collections lengthen, cash pressure.
Profitability inflection timing risk
HighConsolidated PAT -₹73.6 Cr Q1; QoQ deteriorated 35.5% despite 61% growth. Management targets breakeven next 2 quarters, but if capex drag or Tritium margin pressure persists, inflection slides.
Management
Score 6/10. Confident but sometimes vague. Acknowledged challenges (Hyderabad costs, Tritium inventory normalization) candidly. But specific timelines often hedged ('next 2 quarters', 'I'll follow up'). Capacity expansion numbers were inconsistent initially (clarified later). Mixed track record. Delivered 61% revenue growth and ₹1,400 Cr order book (strong). But consolidated profitability has deteriorated QoQ despite growth, missing implied guidance momentum. Tritium turnaround is 2+ years old; trials still mid-stage, not yet converted to contracts.
1 · Q2–Q3 FY27
Hyderabad parallel run costs phase out; EBITDA breakeven target
2 · Q4 FY27 / CY27 start
Tritium Fortune 100 trials close; USD 20–30M contracts expected to convert
3 · H2 FY27
BharatNet ₹700 Cr order pipeline execution; 2,000-tower BSNL Phase 2 allocation
The core risk: management targets EBITDA/PAT breakeven in next 2 quarters (Q2–Q3 FY27), but this is unproven and timing is vague; if costs extend or Tritium trials stall, the loss could persist into H2.
Informational and educational content only. Not investment advice.